Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CalciMedica, Inc. (CALC)
USD0.78
+0.04 (+4.98%)
US NASDAQ Healthcare Biotechnology
Address
505 Coast Boulevard South 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
A. Rachel Leheny
Website
calcimedica.com
IPO
2023-06-14
CIK 1534133 ISIN US38942Q2021
Description
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.78
+0.04 (+4.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.24
Float Shares
8.73M
Free Float %
55.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.63% | -0.62% | +2.01% | -9.97% | -81.13% | -90.44% | -68.65% | -89.21% | -89.21% | -89.21% | -89.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.78
Low
14.00
+1,691.4%
Consensus
266.00
+33,937.1%
Median
392.00
+50,059.9%
High
392.00
+50,059.9%
DCF (Unlevered)
0.00
-100.0%
DCF (Levered)
0.00
-100.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 3 |
266.00
+33,937.1%
|
Quality scores
Altman Z-Score
-37.77
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-61.5% Q1'26: +183.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+133,382.4% Q1'26: +6.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.42× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 25.00M (-100.0%)
|
2.43M
2.43M – 2.43M
-90.3% YoY
|
6.67M
6.67M – 6.67M
+174.0% YoY
|
3.50M
3.50M – 3.50M
-47.5% YoY
|
15.20M
15.20M – 15.20M
+334.3% YoY
|
22.15M
22.15M – 22.15M
+45.7% YoY
|
| EBITDA |
-24.15M
|
-23.12M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-24.20M
|
-23.12M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.70M
est: -16.12M (+15.0%)
|
-29.56M
est: -25.49B (+99.9%)
|
-18.51B
-22.19B – -14.84B
+27.4% YoY
|
-32.37B
-52.21B – -12.54B
-74.9% YoY
|
-33.93B
-53.14B – -14.71B
-4.8% YoY
|
-29.80B
-29.80B – -29.80B
+12.2% YoY
|
-23.49B
-23.49B – -23.49B
+21.2% YoY
|
| SGA |
9.73M
|
7.89M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.22
est: -1.44 (+15.2%)
|
-1.97
est: -1.70 (-15.7%)
|
-1.23
-1.48 – -0.99
+27.6% YoY
|
-2.16
-3.48 – -0.84
-74.9% YoY
|
-2.07
-3.54 – -0.98
+3.9% YoY
|
-1.99
-1.99 – -1.99
+4.3% YoY
|
-1.57
-1.57 – -1.57
+21.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
11
Total invested
249.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fred A. Middleton | 2.55M | 18.30% | 69.0K | 2.48M | 69.0K | 2.48M | IN | — | 2024-11-26 | ↗ |
| 2 | Timothy C. Mills | 2.48M | 17.90% | — | 2.48M | — | 2.48M | PN | — | 2024-11-26 | ↗ |
| 3 | Sanderling Ventures Partners VI, L.P. | 968.6K | 7.10% | — | 968.6K | — | 968.6K | PN | — | 2024-11-26 | ↗ |
| 4 | Co-Investment | 838.5K | 6.20% | — | 838.5K | — | 838.5K | PN | — | 2024-11-26 | ↗ |
| 5 | Laurence W. Lytton | 756.2K | 11.00% | 756.2K | — | 756.2K | — | IN | USA | 2024-07-08 | ↗ |
| 6 | Sanderling Ventures VII, L.P. | 455.9K | 3.40% | — | 455.9K | — | 455.9K | PN | — | 2024-11-26 | ↗ |
| 7 | Sanderling Ventures VII (Canada), L.P. | 119.7K | 0.90% | — | 119.7K | — | 119.7K | PN | — | 2024-11-26 | ↗ |
| 8 | Sanderling Ventures Management VII | 30.6K | 0.20% | — | 30.6K | — | 30.6K | PN | — | 2024-11-26 | ↗ |
| 9 | Sanderling Ventures VII Annex Fund, L.P. | 29.0K | 0.20% | — | 29.0K | — | 29.0K | PN | — | 2024-11-26 | ↗ |
| 10 | Sanderling Ventures Management VI | 22.9K | 0.20% | — | 22.9K | — | 22.9K | PN | — | 2024-11-26 | ↗ |
| 11 | Sanderling VI Limited Partnership | 8.9K | 0.10% | — | 8.9K | — | 8.9K | PN | — | 2024-11-26 | ↗ |
| 12 | Sanderling VI Beteiligungs GmbH & Co KG | 7.5K | 0.10% | — | 7.5K | — | 7.5K | PN | — | 2024-11-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
11
-19 vs prev Q
New positions
5
Closed positions
24
Increased
6
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.30M +— (+0.0%) | 8.57M +4.6M (+114.3%) | 8.67% +8.661 pp | 0.11% +0.048 pp | USD3.84 +71.6% | 8 qtrs — |
| 2 | SOLEUS CAPITAL MANAGEMENT, L.P. | 683.9K +— (+0.0%) | 4.51M +2.4M (+114.3%) | 4.56% +4.556 pp | 0.17% +0.060 pp | USD3.93 +67.7% | 8 qtrs — |
| 3 | AISLING CAPITAL MANAGEMENT LP | 521.1K +— (+0.0%) | 3.43M +1.8M (+114.3%) | 3.48% +3.472 pp | 0.72% +0.366 pp | USD3.93 +67.7% | 8 qtrs — |
| 4 | VANGUARD GROUP INC | 407.8K +31.2K (+8.3%) | 2.69M +1.6M (+136.3%) | 2.72% +2.717 pp | 0.00% +0.000 pp | USD4.16 +58.4% | 8 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 99.8K +935.0 (+0.9%) | 657.6K +359.1K (+120.3%) | 0.67% +0.665 pp | 0.00% +0.000 pp | USD3.66 +80.1% | 10 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 88.3K +18.3K (+26.1%) | 581.9K +366.6K (+170.3%) | 0.59% +0.588 pp | 0.00% +0.001 pp | USD3.98 +65.6% | 5 qtrs — |
| 7 | BOOTHBAY FUND MANAGEMENT, LLC | 76.9K +76.9K (+100.0%) | 506.5K +506.5K (+100.0%) | 0.51% +0.513 pp | 0.01% +0.008 pp | USD6.59 +0.0% | 1 qtrs NEW |
| 8 | ENVESTNET ASSET MANAGEMENT INC | 63.2K -13.5K (-17.6%) | 416.4K +180.5K (+76.5%) | 0.42% -0.090 pp | 0.00% +0.000 pp | USD2.98 +121.1% | 7 qtrs — |
| 9 | MERITAGE PORTFOLIO MANAGEMENT | 61.5K +— (+0.0%) | 405.5K +216.3K (+114.3%) | 0.41% +0.000 pp | 0.03% +0.014 pp | USD3.10 +112.6% | 11 qtrs — |
| 10 | STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD | 53.7K +— (+0.0%) | 353.9K +188.7K (+114.3%) | 0.36% +0.000 pp | 0.01% +0.006 pp | USD3.08 +114.0% | 2 qtrs — |
| 11 | PVG ASSET MANAGEMENT CORP | 45.8K +45.8K (+100.0%) | 302.0K +302.0K (+100.0%) | 0.31% +0.306 pp | 0.64% +0.642 pp | USD6.59 +0.0% | 1 qtrs NEW |
| 12 | SUMMIT FINANCIAL, LLC | 35.5K +10.4K (+41.4%) | 233.8K +156.6K (+202.6%) | 0.24% +0.237 pp | 0.00% +0.002 pp | USD4.11 +60.3% | 2 qtrs — |
| 13 | 180 WEALTH ADVISORS, LLC | 31.9K -10.9K (-25.4%) | 209.9K +78.6K (+59.8%) | 0.21% -0.072 pp | 0.02% +0.008 pp | USD1.70 +287.6% | 4 qtrs — |
| 14 | ATRIA INVESTMENTS, INC | 28.8K -9.3K (-24.4%) | 189.7K +72.5K (+61.9%) | 0.19% +0.192 pp | 0.00% +0.001 pp | USD3.58 +84.1% | 7 qtrs — |
| 15 | CETERA INVESTMENT ADVISERS | 22.3K -3.1K (-12.1%) | 146.9K +68.9K (+88.3%) | 0.15% +0.149 pp | 0.00% +0.000 pp | USD2.89 +128.0% | 6 qtrs — |
| 16 | SOUND VIEW WEALTH ADVISORS GROUP, LLC | 20.1K +— (+0.0%) | 132.5K +70.6K (+114.3%) | 0.13% +0.134 pp | 0.01% +0.005 pp | USD1.60 +311.9% | 3 qtrs — |
| 17 | JANE STREET GROUP, LLC | 19.2K +19.2K (+100.0%) | 126.5K +126.5K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.000 pp | USD6.59 +0.0% | 1 qtrs NEW |
| 18 | J. GOLDMAN & CO LP | 18.9K +— (+0.0%) | 124.6K +66.4K (+114.3%) | 0.13% +0.126 pp | 0.00% +0.002 pp | USD4.25 +55.1% | 7 qtrs — |
| 19 | — | 15.1K +15.1K (+100.0%) | 99.6K +99.6K (+100.0%) | 0.10% +0.101 pp | 0.05% +0.053 pp | USD6.59 +0.0% | 1 qtrs NEW |
| 20 | MILLENNIUM MANAGEMENT LLC | 14.9K -19.5K (-56.8%) | 97.9K -6.0K (-5.7%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD3.84 +71.6% | 8 qtrs — |
| 21 | FIRST MANHATTAN CO. LLC. | 13.2K +— (+0.0%) | 87.2K +46.5K (+114.2%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD1.91 +245.0% | 11 qtrs — |
| 22 | NORTHERN TRUST CORP | 12.5K +12.5K (+100.0%) | 82.6K +82.6K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.000 pp | USD6.59 +0.0% | 1 qtrs NEW |
| 23 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 10.0K +— (+0.0%) | 65.9K +35.1K (+114.3%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD3.08 +114.0% | 2 qtrs — |
| 24 | BANK OF AMERICA CORP /DE/ | 9.0K -5.0 (-0.1%) | 59.5K +31.7K (+114.2%) | 0.06% +0.060 pp | 0.00% +0.000 pp | USD4.17 +58.0% | 11 qtrs — |
| 25 | UBS GROUP AG | 1.1K +1.1K (+6,370.6%) | 7.2K +7.2K (+13,840.4%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD6.51 +1.2% | 11 qtrs — |
| 26 | BROWN BROTHERS HARRIMAN & CO | 308.00 +— (+0.0%) | 2.0K +1.1K (+118.3%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD4.25 +55.1% | 7 qtrs — |
| 27 | ADVISOR GROUP HOLDINGS, INC. | 107.00 -931.0 (-89.7%) | 705.00 -2.5K (-77.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.43 +171.2% | 5 qtrs — |
| 28 | SBI SECURITIES CO., LTD. | 90.00 -32.0 (-26.2%) | 593.00 +218.0 (+58.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.52 +87.2% | 5 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 19.00 +— (+0.0%) | 125.00 +67.0 (+115.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.58 +317.1% | 3 qtrs — |
| 30 | WELLS FARGO & COMPANY/MN | 10.00 +10.0 (+100.0%) | 66.00 +66.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.50 +1.4% | 1 qtrs NEW |
| 31 | TRITONPOINT WEALTH, LLC | — -15.1K (-100.0%) | — -46.5K (-100.0%) | 0.00% -0.101 pp | 0.00% -0.004 pp | USD— | 7 qtrs SOLD |
| 32 | BARCLAYS PLC | — -57.0 (-100.0%) | — -175.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 33 | TOWER RESEARCH CAPITAL LLC (TRC) | — -666.0 (-100.0%) | — -2.0K (-100.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD— | 11 qtrs SOLD |
| 34 | XTX TOPCO LTD | — -15.3K (-100.0%) | — -46.3K (-100.0%) | 0.00% 0.000 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 35 | CITIGROUP INC | — -4.9K (-100.0%) | — -15.2K (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 36 | MORGAN STANLEY | — -856.0 (-100.0%) | — -2.6K (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 71.0K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
937.00
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+937
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-13 | Glicklich Alan | Director | A-Award | A | Director Stock Option (Right to Buy) | 937 | 3.26 | 3.1K | 937 | D | ↗ |
| 2025-09-18 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 3.07 | 7.7K | 84,150 | I | ↗ |
| 2025-09-15 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,400 | 2.68 | 9.1K | 81,650 | I | ↗ |
| 2025-09-12 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 3.12 | 15.6K | 78,250 | I | ↗ |
| 2025-09-09 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,343 | 3.15 | 7.4K | 73,250 | I | ↗ |
| 2025-08-29 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 800 | 2.74 | 2.2K | 70,907 | I | ↗ |
| 2025-08-28 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 9,200 | 2.86 | 26.3K | 70,107 | I | ↗ |
| 2025-08-21 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,508 | 2.79 | 9.8K | 60,907 | I | ↗ |
| 2025-08-20 | Roberts Eric W | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 15,000 | 1.53 | 23.0K | 179,706 | D | ↗ |
| 2025-08-19 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.79 | 2.8K | 55,399 | I | ↗ |
| 2025-08-19 | Hebbar Sudarshan | Officer | P-Purchase | A | Common Stock | 9,563 | 2.82 | 27.0K | 61,539 | D | ↗ |
| 2025-08-15 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,076 | 2.90 | 14.7K | 54,399 | I | ↗ |
| 2025-08-15 | Hebbar Sudarshan | Officer | P-Purchase | A | Common Stock | 4,392 | 2.79 | 12.3K | 51,976 | D | ↗ |
| 2025-08-14 | Hebbar Sudarshan | Officer | P-Purchase | A | Common Stock | 1,584 | 2.59 | 4.1K | 47,584 | D | ↗ |
| 2025-07-28 | Stauderman Kenneth A. | Officer | P-Purchase | A | Common Stock | 1,000 | 3.96 | 4.0K | 12,944 | D | ↗ |
| 2025-07-25 | Stauderman Kenneth A. | Officer | S-Sale | D | Common Stock | 1,000 | 3.65 | 3.7K | 0 | I | ↗ |
| 2025-07-22 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,500 | 3.78 | 5.7K | 49,323 | I | ↗ |
| 2025-07-21 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,500 | 3.37 | 5.1K | 47,823 | I | ↗ |
| 2025-07-21 | Leheny A. Rachel | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 3.40 | 3.4K | 3,500 | I | ↗ |
| 2025-07-18 | WILSON ROBERT N | Director | P-Purchase | A | Common Stock | 4,500 | 2.87 | 12.9K | 422,029 | D | ↗ |
| 2025-07-18 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 2.88 | 5.8K | 46,323 | I | ↗ |
| 2025-07-14 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 6,500 | 2.43 | 15.8K | 44,323 | I | ↗ |
| 2025-07-14 | Leheny A. Rachel | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 2.47 | 6.2K | 2,500 | I | ↗ |
| 2025-07-09 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 1.60 | 8.0K | 37,823 | I | ↗ |
| 2025-07-01 | Stauderman Kenneth A. | Officer | P-Purchase | A | Common Stock | 1,000 | 1.85 | 1.9K | 1,000 | I | ↗ |
| 2025-06-26 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 4,500 | 1.44 | 6.5K | 32,823 | I | ↗ |
| 2025-06-26 | Bardin Stephen | Officer | P-Purchase | A | Common Stock | 2,000 | 1.50 | 3.0K | 3,000 | I | ↗ |
| 2025-06-24 | WILSON ROBERT N | Director | A-Award | A | Director Stock Option (Right to Buy) | 36,562 | 1.53 | 55.9K | 36,562 | D | ↗ |
| 2025-06-24 | Stauderman Kenneth A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 47,125 | 1.53 | 72.1K | 47,125 | D | ↗ |
| 2025-06-24 | Shaw Allan | Director | A-Award | A | Director Stock Option (Right to Buy) | 26,250 | 1.53 | 40.2K | 26,250 | D | ↗ |
| 2025-06-24 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 72,750 | 1.53 | 111.3K | 72,750 | D | ↗ |
| 2025-06-24 | MIDDLETON FRED A | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 6,562 | 1.53 | 10.0K | 6,562 | D | ↗ |
| 2025-06-24 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 77,625 | 1.53 | 118.8K | 77,625 | D | ↗ |
| 2025-06-24 | Hebbar Sudarshan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 83,300 | 1.53 | 127.4K | 83,300 | D | ↗ |
| 2025-06-24 | Guerard Frederic | Director | A-Award | A | Director Stock Option (Right to Buy) | 5,000 | 1.53 | 7.7K | 5,000 | D | ↗ |
| 2025-06-24 | Glicklich Alan | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 1.65 | 16.5K | 10,000 | D | ↗ |
| 2025-06-24 | Dunn Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 47,125 | 1.53 | 72.1K | 47,125 | D | ↗ |
| 2025-06-24 | Bardin Stephen | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 1.53 | 30.6K | 20,000 | D | ↗ |
| 2025-06-11 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 1.85 | 9.3K | 28,323 | I | ↗ |
| 2025-06-06 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 1.78 | 8.9K | 23,323 | I | ↗ |
| 2025-06-05 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,100 | 1.70 | 8.7K | 18,323 | I | ↗ |
| 2025-05-30 | Bardin Stephen | Officer | P-Purchase | A | Common Stock | 1,000 | 1.69 | 1.7K | 41,000 | D | ↗ |
| 2025-04-23 | Stauderman Kenneth A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 1.53 | 191.3K | 125,000 | D | ↗ |
| 2025-04-23 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 160,000 | 1.53 | 244.8K | 160,000 | D | ↗ |
| 2025-04-23 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 285,000 | 1.53 | 436.1K | 285,000 | D | ↗ |
| 2025-04-23 | Hebbar Sudarshan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 175,000 | 1.53 | 267.8K | 175,000 | D | ↗ |
| 2025-04-23 | Dunn Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 1.53 | 191.3K | 125,000 | D | ↗ |
| 2025-04-23 | Bardin Stephen | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 130,000 | 1.53 | 198.9K | 130,000 | D | ↗ |
| 2025-04-05 | Stauderman Kenneth A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 65,124 | 0.59 | 38.1K | 65,124 | D | ↗ |
| 2025-04-05 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 83,358 | 0.59 | 48.8K | 83,358 | D | ↗ |
| 2025-04-05 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 148,482 | 0.59 | 86.9K | 148,482 | D | ↗ |
| 2025-04-05 | Hebbar Sudarshan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,173 | 0.59 | 53.3K | 91,173 | D | ↗ |
| 2025-04-05 | Dunn Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 65,124 | 0.59 | 38.1K | 65,124 | D | ↗ |
| 2025-04-05 | Bardin Stephen | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 67,728 | 0.59 | 39.6K | 67,728 | D | ↗ |
| 2025-01-15 | Glicklich Alan | Director | A-Award | A | Director Stock Option (Right to Buy) | 20,000 | 3.02 | 60.4K | 20,000 | D | ↗ |
| 2024-12-06 | MIDDLETON FRED A | Director / 10% Owner | P-Purchase | A | Common Stock | 4,800 | 2.65 | 12.7K | 36,514 | D | ↗ |
| 2024-11-13 | Bardin Stephen | Officer | — | — | Employee Stock Option (Right to Buy) | 100,000 | 3.50 | 350.0K | 0 | D | ↗ |
| 2024-11-01 | WILSON ROBERT N | Director | P-Purchase | A | Common Stock | 53,333 | 3.75 | 200.0K | 417,529 | D | ↗ |
| 2024-11-01 | Sanderling Venture Partners VI Co Investment Fund LP | 10% Owner | P-Purchase | A | Common Stock | 86,867 | 3.75 | 325.8K | 814,300 | D | ↗ |
| 2024-11-01 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 53,333 | 3.75 | 200.0K | 164,706 | D | ↗ |
| 2024-11-01 | MIDDLETON FRED A | Director / 10% Owner | P-Purchase | A | Common Stock | 86,867 | 3.75 | 325.8K | 814,300 | I | ↗ |
| 2024-11-01 | Leheny A. Rachel | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 3.75 | 75.0K | 130,926 | D | ↗ |
| 2024-09-09 | Dunn Michael J. | Officer | M-Exempt | A | Common Stock | 11,761 | 1.39 | 16.3K | 11,761 | — | ↗ |
| 2024-08-27 | WILSON ROBERT N | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-08-27 | Stauderman Kenneth A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,500 | 4.16 | 260.0K | 62,500 | — | ↗ |
| 2024-08-27 | Shaw Allan | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-08-27 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 77,500 | 4.16 | 322.4K | 77,500 | — | ↗ |
| 2024-08-27 | MIDDLETON FRED A | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-08-27 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 115,000 | 4.16 | 478.4K | 115,000 | — | ↗ |
| 2024-08-27 | Hebbar Sudarshan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 82,500 | 4.16 | 343.2K | 82,500 | — | ↗ |
| 2024-08-27 | Guerard Frederic | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-08-27 | Dunn Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,500 | 4.16 | 260.0K | 62,500 | — | ↗ |
| 2024-08-27 | BJERKHOLT ERIC | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-08-23 | WILSON ROBERT N | Director | P-Purchase | A | Common Stock | 54,000 | 3.72 | 200.8K | 364,196 | — | ↗ |
| 2024-08-23 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 3.58 | 7.2K | 46,894 | — | ↗ |
| 2024-08-21 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 4.04 | 20.2K | 44,894 | — | ↗ |
| 2024-06-28 | WILSON ROBERT N | Director | P-Purchase | A | Common Stock | 51,278 | 3.52 | 180.5K | 310,196 | — | ↗ |
| 2024-06-27 | WILSON ROBERT N | Director | P-Purchase | A | Common Stock | 8,443 | 3.23 | 27.3K | 258,918 | — | ↗ |
| 2024-06-27 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 3.22 | 16.1K | 10,223 | — | ↗ |
| 2024-05-17 | Geffken Daniel E. | Officer | A-Award | A | Warrant | 10,000 | 5.45 | 54.5K | 10,000 | — | ↗ |
| 2024-04-02 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,254 | 3.90 | 12.7K | 39,894 | — | ↗ |
| 2024-04-01 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 746 | 3.90 | 2.9K | 36,640 | — | ↗ |
| 2024-03-28 | WILSON ROBERT N | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-03-28 | Stauderman Kenneth A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,500 | 4.16 | 260.0K | 62,500 | — | ↗ |
| 2024-03-28 | Shaw Allan | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-03-28 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 77,500 | 4.16 | 322.4K | 77,500 | — | ↗ |
| 2024-03-28 | MIDDLETON FRED A | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-03-28 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 115,000 | 4.16 | 478.4K | 115,000 | — | ↗ |
| 2024-03-28 | Hebbar Sudarshan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 82,500 | 4.16 | 343.2K | 82,500 | — | ↗ |
| 2024-03-28 | Guerard Frederic | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-03-28 | Dunn Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,500 | 4.16 | 260.0K | 62,500 | — | ↗ |
| 2024-03-28 | BJERKHOLT ERIC | Director | A-Award | A | Director Stock Option (Right to Buy) | 10,000 | 4.16 | 41.6K | 10,000 | — | ↗ |
| 2024-02-05 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 91,086 | 4.27 | 388.6K | 111,373 | — | ↗ |
| 2024-01-23 | WILSON ROBERT N | Director | A-Award | A | Warrant | 34,157 | 7.15 | 244.2K | 34,157 | — | ↗ |
| 2024-01-23 | Sanderling Venture Partners VI LP | 10% Owner | P-Purchase | A | Warrant | 72,338 | 7.15 | 517.2K | 72,338 | — | ↗ |
| 2024-01-23 | MIDDLETON FRED A | Director / 10% Owner | P-Purchase | A | Common Stock | 28,744 | 3.70 | 106.4K | 30,292 | — | ↗ |
| 2024-01-23 | Leheny A. Rachel | Director / Officer / 10% Owner | A-Award | A | Common Stock | 91,086 | 4.27 | 388.6K | 109,926 | — | ↗ |
| 2023-05-17 | Roberts Eric W | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,000 | 2.68 | 8.0K | 3,000 | I | ↗ |
| 2023-03-20 | Sanderling Venture Partners VI LP | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-20 | Roberts Eric W | Director / Officer / 10% Owner | A-Award | A | Common Stock | 356,989 | 0.00 | — | 356,989 | — | ↗ |
| 2023-03-20 | MIDDLETON FRED A | Director / 10% Owner | A-Award | A | Warrant | 8,393 | 27.94 | 234.5K | 8,393 | — | ↗ |
| 2010-03-19 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 30,000 | 1.14 | 34.2K | 1,645,000 | — | ↗ |
| 2010-03-18 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 12,328 | 1.25 | 15.4K | 1,615,000 | — | ↗ |
| 2010-03-16 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 1.25 | 2.5K | 1,602,672 | — | ↗ |
| 2010-03-09 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 20,029 | 1.25 | 25.0K | 1,600,672 | — | ↗ |
| 2010-03-01 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 1,440 | 1.25 | 1.8K | 1,370,025 | — | ↗ |
| 2010-02-26 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 10,960 | 1.25 | 13.7K | 1,368,585 | — | ↗ |
| 2010-02-23 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 1,300 | 1.25 | 1.6K | 1,567,783 | — | ↗ |
| 2010-02-11 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 8,900 | 1.25 | 11.1K | 1,566,483 | — | ↗ |
| 2009-12-31 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 170 | 1.25 | 212.50 | 1,557,583 | — | ↗ |
| 2009-12-28 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 1.23 | 1.2K | 1,557,413 | — | ↗ |
| 2009-12-10 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 13,406 | 1.26 | 16.9K | 1,305,348 | — | ↗ |
| 2009-12-09 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 37,120 | 1.27 | 47.1K | 1,291,942 | — | ↗ |
| 2009-12-07 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 700 | 1.17 | 819.00 | 1,496,154 | — | ↗ |
| 2009-12-04 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 1.25 | 18.8K | 1,495,454 | — | ↗ |
| 2009-12-03 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 1,700 | 1.23 | 2.1K | 1,480,454 | — | ↗ |
| 2009-12-01 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 14,800 | 1.22 | 18.1K | 1,478,754 | — | ↗ |
| 2009-11-30 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 24,200 | 1.18 | 28.6K | 1,463,954 | — | ↗ |
| 2009-11-27 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 13,162 | 1.19 | 15.7K | 1,439,754 | — | ↗ |
| 2009-11-25 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 4,320 | 1.19 | 5.1K | 1,193,582 | — | ↗ |
| 2009-11-23 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 20,170 | 1.12 | 22.6K | 1,421,592 | — | ↗ |
| 2009-11-20 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 1.09 | 2.2K | 1,401,422 | — | ↗ |
| 2009-11-19 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 53,858 | 1.11 | 59.8K | 1,399,422 | — | ↗ |
| 2009-11-18 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 1.16 | 11.6K | 1,345,564 | — | ↗ |
| 2009-11-12 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 7,980 | 1.00 | 8.0K | 1,117,762 | — | ↗ |
| 2009-11-11 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 14,221 | 0.95 | 13.5K | 1,326,064 | — | ↗ |
| 2009-11-10 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 55,000 | 0.99 | 54.5K | 1,311,843 | — | ↗ |
| 2009-11-09 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 10,710 | 0.99 | 10.6K | 1,051,612 | — | ↗ |
| 2009-11-06 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 9,198 | 1.00 | 9.2K | 1,244,243 | — | ↗ |
| 2009-11-05 | HOVDE ERIC D | 10% Owner | P-Purchase | A | Common Stock | 88,842 | 0.95 | 84.4K | 1,235,045 | — | ↗ |
| 2009-11-04 | HOVDE ERIC D | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,146,203 | — | ↗ |
| 2009-01-09 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 52,900 | 1.16 | 61.4K | 471,675 | — | ↗ |
| 2009-01-07 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 4,000 | 1.00 | 4.0K | 418,775 | — | ↗ |
| 2009-01-02 | ARENS GEOFFREY W | Director | A-Award | A | Common Stock - $.05 par value | 35,714 | 0.56 | 20.0K | 40,159 | — | ↗ |
| 2008-08-15 | ING GROEP NV | Director / 10% Owner | P-Purchase | A | Common Stock | 125,000 | 2.82 | 351.9K | 1,755,683 | — | ↗ |
| 2008-01-02 | ARENS GEOFFREY W | Director | A-Award | A | Common Stock - $.05 par value | 3,515 | 5.69 | 20.0K | 4,445 | — | ↗ |
| 2007-08-23 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock $.05 par value | 3,200 | 13.99 | 44.8K | 414,775 | — | ↗ |
| 2007-08-20 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock $.05 par value | 2,100 | 14.12 | 29.7K | 411,575 | — | ↗ |
| 2007-08-17 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock $.05 par value | 450 | 14.14 | 6.4K | 409,475 | — | ↗ |
| 2007-08-16 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock $.05 par value | 3,200 | 13.99 | 44.8K | 409,025 | — | ↗ |
| 2007-06-21 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock $.05 par value | 3,000 | 16.90 | 50.7K | 405,825 | — | ↗ |
| 2007-06-21 | ING GROEP NV | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-06 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 1,000 | 17.59 | 17.6K | 402,825 | — | ↗ |
| 2007-06-04 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 2,000 | 17.46 | 34.9K | 401,825 | — | ↗ |
| 2007-05-31 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 2,000 | 17.45 | 34.9K | 399,825 | — | ↗ |
| 2007-05-15 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 1,000 | 17.20 | 17.2K | 397,825 | — | ↗ |
| 2007-05-11 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 13,000 | 17.50 | 227.5K | 396,825 | — | ↗ |
| 2007-04-12 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 1,000 | 18.40 | 18.4K | 383,825 | — | ↗ |
| 2007-04-11 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 8,000 | 18.48 | 147.8K | 382,825 | — | ↗ |
| 2007-01-03 | ARENS GEOFFREY W | Director | A-Award | A | Common Stock - $.05 par value | 930 | 21.50 | 20.0K | 930 | — | ↗ |
| 2006-12-13 | Pacini Raymond J | Director / Officer | S-Sale | D | Common Stock - $.05 par value | 1,065 | 21.01 | 22.4K | 374,825 | — | ↗ |
| 2006-12-11 | Pacini Raymond J | Director / Officer | S-Sale | D | Common Stock - $.05 par value | 735 | 21.00 | 15.4K | 375,890 | — | ↗ |
| 2006-10-17 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 19,200 | 18.30 | 351.3K | 1,003,768 | — | ↗ |
| 2006-10-16 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 25,000 | 18.59 | 464.6K | 1,022,968 | — | ↗ |
| 2006-10-13 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 21,500 | 18.42 | 396.1K | 1,047,968 | — | ↗ |
| 2006-10-12 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 17,500 | 18.35 | 321.1K | 1,069,468 | — | ↗ |
| 2006-10-11 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 10,000 | 18.33 | 183.3K | 1,086,968 | — | ↗ |
| 2006-10-10 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 9,500 | 18.55 | 176.3K | 1,096,968 | — | ↗ |
| 2006-10-09 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 8,280 | 18.48 | 153.0K | 1,106,468 | — | ↗ |
| 2006-10-06 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 4,000 | 19.06 | 76.3K | 1,114,748 | — | ↗ |
| 2006-10-05 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 11,000 | 19.18 | 211.0K | 1,118,748 | — | ↗ |
| 2006-10-04 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 8,800 | 18.99 | 167.1K | 1,129,748 | — | ↗ |
| 2006-10-02 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | S-Sale | D | Common Stock | 5,200 | 20.10 | 104.5K | 1,138,548 | — | ↗ |
| 2006-08-08 | Pacini Raymond J | Director / Officer | P-Purchase | A | Common Stock - $.05 par value | 264,996 | 4.50 | 1.19M | 376,625 | — | ↗ |
| 2006-03-29 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | J-Other | D | Common Stock | 10,000 | 36.66 | 366.6K | 1,143,748 | — | ↗ |
| 2005-11-14 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 1,500 | 37.16 | 55.7K | 1,143,748 | — | ↗ |
| 2005-11-11 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 37.11 | 74.2K | 1,142,248 | — | ↗ |
| 2005-11-10 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 9,100 | 37.06 | 337.2K | 1,140,248 | — | ↗ |
| 2005-11-09 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 4,207 | 37.09 | 156.0K | 1,131,148 | — | ↗ |
| 2005-11-08 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 11,500 | 36.93 | 424.6K | 1,126,941 | — | ↗ |
| 2005-11-07 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 4,522 | 37.16 | 168.0K | 1,115,441 | — | ↗ |
| 2005-11-04 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 1,944 | 37.17 | 72.3K | 1,110,919 | — | ↗ |
| 2005-11-03 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,700 | 37.05 | 100.0K | 1,108,975 | — | ↗ |
| 2005-11-02 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 36.16 | 36.2K | 1,106,275 | — | ↗ |
| 2005-11-01 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,454 | 35.47 | 87.0K | 1,105,275 | — | ↗ |
| 2005-10-31 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,900 | 35.44 | 102.8K | 1,102,821 | — | ↗ |
| 2005-10-28 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 5,300 | 35.05 | 185.8K | 1,099,921 | — | ↗ |
| 2005-10-27 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,865 | 34.97 | 100.2K | 1,094,621 | — | ↗ |
| 2005-10-25 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 4,113 | 34.89 | 143.5K | 1,091,756 | — | ↗ |
| 2005-10-24 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 35.00 | 70.0K | 1,085,643 | — | ↗ |
| 2005-10-21 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 6,518 | 34.80 | 226.8K | 1,105,643 | — | ↗ |
| 2005-10-20 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 6,518 | 34.80 | 226.8K | 1,085,643 | — | ↗ |
| 2005-10-19 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 4,500 | 34.81 | 156.6K | 1,075,692 | — | ↗ |
| 2005-10-18 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 5,271 | 34.91 | 184.0K | 1,071,192 | — | ↗ |
| 2005-10-17 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | P-Purchase | A | Common Stock | 3,100 | 34.65 | 107.4K | 1,065,921 | — | ↗ |
| 2005-10-05 | MELLON HBV ALTERNATIVE STRATEGIES LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,062,821 | — | ↗ |
| 2005-06-10 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 114,082 | 29.36 | 3.35M | 0 | — | ↗ |
| 2005-06-07 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 1,000 | 29.49 | 29.5K | 995,950 | — | ↗ |
| 2005-06-06 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 100 | 29.29 | 2.9K | 996,950 | — | ↗ |
| 2005-06-03 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 1,000 | 29.20 | 29.2K | 1,005,738 | — | ↗ |
| 2005-06-02 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 617 | 29.13 | 18.0K | 1,006,738 | — | ↗ |
| 2005-05-26 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 5,000 | 29.49 | 147.4K | 1,008,600 | — | ↗ |
| 2005-05-25 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 2,100 | 29.28 | 61.5K | 225,212 | — | ↗ |
| 2005-05-24 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 110 | 29.38 | 3.2K | 1,016,798 | — | ↗ |
| 2005-05-23 | Jarvis David R | 10% Owner | S-Sale | D | Common Stock | 13,335 | 29.35 | 391.4K | 1,025,596 | — | ↗ |
| 2005-03-14 | Jarvis David R | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 25.52 | 382.8K | 1,038,931 | — | ↗ |
| 2005-03-11 | Jarvis David R | 10% Owner | P-Purchase | A | Common Stock | 600 | 25.65 | 15.4K | 1,030,243 | — | ↗ |
| 2005-03-10 | Jarvis David R | 10% Owner | P-Purchase | A | Common Stock | 100 | 25.52 | 2.6K | 1,029,643 | — | ↗ |
| 2005-03-07 | ARENS GEOFFREY W | Director | J-Other | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-03-02 | Jarvis David R | 10% Owner | P-Purchase | A | Common Stock | 11,156 | 26.24 | 292.8K | 1,038,231 | — | ↗ |
Executive team
Top executives
Shares Outstanding
15.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Frederic Guerard Former Chief Executive Officer | 239.1K | — | — | 572.00 | 60.0K | 1.80M | 2.10M | 0.03% | ↗ |
| 2 | 2023 | Robert Breuil Former Chief Financial Officer | 142.7K | — | — | 4.00 | 60.0K | 960.9K | 1.16M | 0.00% | ↗ |
| 3 | 2023 | Parisa Zamiri Former Chief Medical Officer | 79.5K | — | — | 4.1K | — | 972.9K | 1.06M | 0.39% | ↗ |
| 4 | 2023 | A. Rachel Leheny, Ph.D. Chief Executive Officer | 318.9K | 350.0K | — | 248.6K | 93.6K | 1.8K | 1.01M | 24.55% | ↗ |
| 5 | 2023 | Eric. W. Roberts Chief Business Officer | 282.0K | 300.0K | — | 136.7K | 85.7K | 11.4K | 815.8K | 16.76% | ↗ |
| 6 | 2023 | Kenneth A. Stauderman, Ph.D. Chief Scientific Officer | 266.7K | 210.0K | — | 155.4K | 62.9K | 1.9K | 696.9K | 22.30% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kenneth A. Stauderman | Co-Founder & Chief Scientific Officer | 615.6K | — |
| A. Rachel Leheny | Chief Executive Officer & Director | 430.9K | — |
| Sudarshan Hebbar | Chief Medical Officer | 430.8K | — |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 403.8K | male |
| Michael J. Dunn | President & Chief Operating Officer | — | male |
| John Dunn | General Counsel | — | male |
| Stefan Feske | Co-Founder and Scientific Advisor | — | — |
| Stephen Bardin | Chief Financial Officer | — | male |
| Anjana Rao | Co-Founder and Scientific Advisor | — | — |
| Patrick Hogan | Co-Founder and Scientific Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CALC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
